New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
07:47 EDTSHPG, ABBVAbbVie cheapest Pharma stock under coverage, says Jefferies
Jefferies says AbbVie (ABBV) is the cheapest Pharma stock in its coverage universe and its Top Global Pick. The firm expects earnings momentum to be driven by Humira growth, the HCV launch and the acquisition of Shire (SHPG). It keeps a Buy rating on AbbVie with an $85 price target.
News For ABBV;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
16:50 EDTABBVAbbVie extends exchange offer to acquire Pharmacyclics
Subscribe for More Information
April 15, 2015
19:08 EDTABBVEnanta confirms AbbVie hepatitis C treatment granted priority review in Japan
Subscribe for More Information
19:03 EDTABBVAbbVie's chronic hepatitis C treatment granted priority review in Japan
Subscribe for More Information
April 13, 2015
14:07 EDTABBVEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
10:00 EDTABBVOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:34 EDTABBVAbbVie upgraded on Imbruvica outlook at BMO Capital
Subscribe for More Information
07:20 EDTSHPGShire price target raised to $288 from $267 at JPMorgan
JPMorgan raised its price target for Shire to $288 after lifting its estimates for Lifitegrast in dry eye following the FDA's Priority Review designation. The firm believes the FDA is very likely to approve the application in October of this year, without waiting for the third Phase III study late 2015. It upped its 2020 Lifitegrast forecasts by $600M to $900M and reiterates an Overweight rating on Shire.
07:02 EDTABBVAbbVie upgraded to Outperform from Market Perform at BMO Capital
April 9, 2015
13:27 EDTSHPGShire announces FDA Priority Review designation for lifitegrast
Subscribe for More Information
10:48 EDTSHPGDeutsche compares PTC Therapeutics to Vertex, boosts target by $40
Subscribe for More Information
05:27 EDTSHPGShire reports results from three placebo-controlled Phase 2 studies of SHP625
Subscribe for More Information
April 8, 2015
05:30 EDTABBVEnanta announces data on regimens containing protease inhibitors paritaprevir
Subscribe for More Information
April 7, 2015
10:10 EDTSHPGJazz patent on Xyrem latest to be challenged by Kyle Bass
Subscribe for More Information
08:10 EDTSHPGShire shares pricing in worst case scenario for patents, says Citigroup
Subscribe for More Information
07:31 EDTABBVBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information
07:13 EDTSHPGShire patent challenges only modest threat, says Jefferies
Subscribe for More Information
05:23 EDTSHPGShire reaches agreement with FDA on clear regulatory path for SHP465
Shire announces that it has reached an agreement with the FDA on a clear regulatory path for SHP465, an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder, or ADHD, in adults. Shire has agreed with the FDA to conduct a short-term efficacy and safety study in pediatric patients with ADHD. While Shire intends to pursue an adult indication, the FDA is requesting this additional pediatric data to better understand the potential effects of SHP465 on children with ADHD in the event of use in this population. The company anticipates the clinical trial's first patient, first visit to take place in August 2015, with study completion targeted by the last quarter of 2016. Shire then expects to submit to the FDA by 2Q17 a Class 2 resubmission for approval of SHP465 as a treatment for ADHD in adults, which typically entails a 6-month review. Pending FDA approval, Shire anticipates launching the medicine in the second half of 2017. This update follows Shire's announcement on October 9, 2014, that it was engaging the FDA to determine the parameters of clinical data requirements in order to submit the Class 2 resubmission.
April 6, 2015
09:09 EDTSHPGShire says will defend patents 'vigorously' after Hayman petitions
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use